SCHEMBL13197831

SCHEMBL13197831

CC(CO)NC(=O)c1nc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cn1CC=C(Cl)Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.42
AHR P35869 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
MCHR1 Q99705 2/20 0.39
IGF1R P08069 2/20 0.38
RAF1 P04049 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
EPHB4 P54760 1/20 0.37
TEK Q02763 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13197846 0.92 EPHX2 (0.42) EPHX2AHRALDH1A1HPGDMCHR1
SCHEMBL13197837 0.86 SMN1; SMN2 (0.48) EPHX2AHRALDH1A1HPGDIGF1R
SCHEMBL13197827 0.85 MCHR1 (0.44) EPHX2MCHR1IGF1RRAF1MAPT
SCHEMBL2876477 0.85 EPHX2 (0.49) EPHX2MCHR1IGF1REPHB4TEK
SCHEMBL13197853 0.85 EPHX2 (0.43) EPHX2AHRALDH1A1HPGDMCHR1
SCHEMBL13197893 0.85 EPHX2 (0.40) EPHX2ALDH1A1HPGDMCHR1IGF1R
SCHEMBL13197829 0.84 MCHR1 (0.43) EPHX2MCHR1IGF1RMAPTEPHB4
SCHEMBL13197817 0.84 EPHX2 (0.44) EPHX2AHRALDH1A1HPGDMCHR1
SCHEMBL13197822 0.82 EPHX2 (0.43) EPHX2AHRALDH1A1HPGDIGF1R
SCHEMBL13197886 0.82 MCHR1 (0.41) EPHX2MCHR1IGF1RRAF1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 EPHX2 3922/4885AHR 3830/4885ALDH1A1 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.